Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment for primary advanced or recurrent endometrial cancer: SMC2767 (pembrolizumab with carboplatin & paclitaxel) & SMC2797 (durvalumab with carboplatin & paclitaxel)

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

The aim of this work was to capture real-world evidence from Scotland on the use of Systemic Anti-Cancer Therapy (SACT) for first-line treatment of adults with either primary advanced or recurrent endometrial cancer. The Scottish Medicines Consortium (SMC) requested this work to describe current SACT use in this population, and to assist SMC members when considering submissions for the new use of the following medicines:

• Durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer (SMC2797).
• Pembrolizumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer (SMC2767).

The objectives were to:

• Determine the number of adult patients who received first-line SACT for primary advanced or recurrent endometrial cancer.
• Describe the baseline characteristics of patients receiving first-line SACT for primary advanced or recurrent endometrial cancer.
• Provide information on treatment pathways including prior adjuvant / neo-adjuvant and subsequent SACT for these patients.

Main Points

• 266 patients were prescribed first-line SACT for primary advanced or recurrent endometrial cancer between 1st February 2021 and 31st January 2025.
• Most patients (n=201, 76%) received carboplatin + paclitaxel as first-line SACT for primary advanced or recurrent endometrial cancer.

KEY: WoSCAN - West of Scotland Cancer Network; NCA - North Cancer Alliance; SCAN - South East Cancer Network. ¹ Includes the following regimens: carboplatin + nab-paclitaxel; carboplatin + gemcitabine; liposomal doxorubicin; nab-paclitaxel; cisplatin; docetaxel + gemcitabine; doxorubicin; and epirubicin; ² Using SIMD 2020 definition.

Background

Cancer Medicines Outcome Programme (CMOP) Background

The overall vision of the Cancer Medicines Outcomes Programme-Public Health Scotland (CMOP-PHS) collaboration is to better understand the real-life impact of cancer medicines on cancer patients in Scotland. Healthcare professionals may then use these findings to help support clinical decision making and enable a more bespoke and individualised approach to the provision of cancer care for all our patients. Developing, and refining, a robust and reliable process means that cancer medicines intelligence may be routinely generated to support informed decision making at individual, local, and national levels.

Together with information available from clinical trials, this additional knowledge is intended to help NHS Scotland deliver a more personalised approach to providing cancer care, and to help ensure the safe and effective use of medicines.

The CMOP-PHS collaboration builds on established clinical engagement across NHS Scotland Health Boards and integrates with key stakeholders, thereby bringing together clinical, academic and data analysis skills from the NHS, Public Health Scotland, and academia, alongside the patient and public voice. The collaboration provides organisational memory and supports workforce resilience, embedding robust processes to routinely generate and report real-world evidence (RWE). This supports the provision of patient-centred cancer care and decision-making processes, setting Scotland apart as a centre of excellence in the cancer medicines RWE arena.

Scottish Medicines Consortium

The Scottish medicines Consortium (SMC) considers a broad range of evidence to decide which medicines should be accepted for use nationally by NHSScotland. The committee is composed of clinicians, pharmacists, NHS board representatives, the pharmaceutical industry, and the public. More information can be found via the SMC website.

This report will be used by the New Drugs Committee (NDC) in their assessment of both durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer (SMC2797) and pembrolizumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer (SMC2767). If the NDC do not accept these, the SMC committee will review them. If reviewed by SMC, they will publish their advice via their website.